RT Book, Section
A1 Gonzalez, Alex
A2 Keuroghlian, Alex S.
A2 Potter, Jennifer
A2 Reisner, Sari L.
SR Print(0)
ID 1184177127
T1 Screening for Cancer and Cardiovascular
T2 Transgender and Gender Diverse Health Care: The Fenway Guide
YR 2022
FD 2022
PB McGraw Hill
PP New York, NY
SN 9781260459937
LK accessmedicine.mhmedical.com/content.aspx?aid=1184177127
RD 2024/04/24
AB Heart  disease  and  cancer  are  the  two  leading  causes  of  death  in  the  general  population  in  the  United  States,1  but  their  impact  on  transgender  and  gender  diverse  (TGD)  people  is  poorly  understood.  Gender-affirming  hormone  therapy  (GAHT)  can  play  a  role  in  the  development  of  certain  cancers,  and  may  worsen  some  risk  factors  for  cardiovascular  disease.  Societal  and  health  care  sector  marginalization  of  TGD  people—via  economic  disenfranchisement,  increased  risky  behavior,  decreased  access  to  care,  decreased  patient  willingness  to  seek  care,  and  increased  stigma—can  contribute  to  higher  oncologic  and  cardiovascular  risk  as  well.  This  chapter  will  review  what  we  know  about  cancer  and  cardiovascular  disease  epidemiology  in  TGD  people  as  well  as  how  to  approach  screening  for  these  diseases  in  a  primary  care  setting.